ReDormin® (Ze91019) has been shown to assist in the relief of sleeplessness and insomnia. ReDormin contains standardised whole plant extracts of Valerian (Valeriana officinalis) and Hops (Humulus lupulus), in a combination that has been demonstrated, in clinical trials, to improve sleep quality.
Clinical trials have shown that ReDormin can significantly improve sleep:
- Decreasing the time taken to get to sleep (sleep latency)
- Improving sleep quality, so that you wake less during the night and rise feeling more refreshed
Situations that may benefit from ReDormin include:
- Difficulty getting to sleep
- Difficulty staying asleep i.e. waking during the night
- Trying to regulate sleep patterns e.g. shift workers, jet lag, chronic sleep disturbance
- Wanting to improve the quality of sleep, leading to feeling more refreshed the following day
ReDormin’s sedative effects have been demonstrated in a placebo-controlled study of 48 volunteers. Subjects were hyperaroused (via administration of 200 mg caffeine) and quantitative EEGs recorded immediately, then every 30 minutes for 2 hours. Changes in alpha and beta waves (consistent with hyperarousal) were neutralised in just 30 minutes by ReDormin. As hyperarousal is a common aetiology of insomnia, this helps to explain ReDormin’s clinical effects.
A more recent randomised, double-blind, placebo controlled trial used objective sleep measurements to demonstrate that patients with prolonged sleep latency (? 30 min) had a significant reduction in time taken to get to sleep after ReDormin treatment, compared to placebo.ReDormin has also been shown to increase slow wave activity compared to placebo.
ReDormin treatment resulted in a significant reduction in the time to get sleep and time spent awake. Patients also reported feeling more refreshed in the morning after taking ReDormin.
Finally, an open multi-centre trial of 3,447 patients who had experienced sleep problems for longer than 4 weeks, showed a significant reduction in the number of patients waking twice or more per night (77% baseline vs 23% after ReDormin). The efficacy and tolerability were also rated ‘good’ or ‘very good’ by the treating doctors (75% and 98% respectively).
- Excellent tolerability (average of one reported adverse reaction for every 0.9 million daily doses)
- No known interactions
- Non-addictive (no record of dependency)
Results from large-scale clinical trials suggest that ReDormin improves sleep quality and relieves insomnia. This is supported by the millions of doses purchased worldwide every year. In fact, 300 million doses of ReDormin have been sold worldwide since its launch in 1996. ReDormin has been shown to be very well tolerated, with no known risk of dependency
Adults and adolescents 12 years and over: 2 tablets 1 hour before bed. While some people may notice an immediate improvement, it is likely to take several weeks to see the full benefits, and 1 month of continued treatment is usually recommended.
ReDormin contains a unique formulation (Ze 91019) of standardised plant extracts, manufactured in Switzerland:
- Valeriana officinalis (Valerian) root
- Humulus lupulus (Hops) fruit
Sleep regulation is a complex area of study. There are two underlying cycles that constitute normal sleep structure: the circadian rhythm (balance of sleep-wake phases) and the homeostatic process (increase of readiness to sleep). ReDormin positively affects both cycles through its action on melatonin and adenosine.